Volume 8, Issue 5, Pages (May 2017)

Slides:



Advertisements
Similar presentations
Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Advertisements

Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis  Dariush Haghmorad, Mohammad Bagher.
Third-party Mesenchymal Stem Cells Improved Human Islet Transplantation in a Humanized Diabetic Mouse Model  Hao Wu, Di Wen, Ram I Mahato  Molecular Therapy 
Volume 140, Issue 3, Pages e4 (March 2011)
Volume 149, Issue 1, Pages (July 2015)
Volume 19, Issue 1, Pages (January 2014)
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β- Defensins via Induction of Regulatory T Cells  Anika Bruhs, Thomas.
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ  Keiji Tanese, Yuuri Hashimoto, Zuzana Berkova, Yuling Wang, Felipe.
Volume 25, Issue 2, Pages (August 2006)
Glycoprotein Nonmelanoma Clone B Regulates the Crosstalk between Macrophages and Mesenchymal Stem Cells toward Wound Repair  Bing Yu, Talib Alboslemy,
Volume 140, Issue 3, Pages e4 (March 2011)
Volume 143, Issue 5, Pages (November 2012)
Volume 78, Issue 11, Pages (December 2010)
Volume 43, Issue 4, Pages (October 2015)
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis  Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,
Tatsukuni Ohno, Yuta Kondo, Chenyang Zhang, Siwen Kang, Miyuki Azuma 
Volume 35, Issue 4, Pages (October 2011)
Volume 149, Issue 1, Pages (July 2015)
Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus- Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration.
Volume 25, Issue 3, Pages (September 2006)
The Protective Effects of Melittin on Propionibacterium acnes–Induced Inflammatory Responses In Vitro and In Vivo  Woo-Ram Lee, Kyung-Hyun Kim, Hyun-Jin.
Volume 140, Issue 3, Pages e4 (March 2011)
Volume 16, Issue 11, Pages (September 2016)
Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic.
Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Volume 13, Issue 2, Pages (August 2013)
IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft- Versus-Host Disease  Doanh Le Huu, Takashi Matsushita, Guihua Jin, Yasuhito.
Self-Antigen Presentation by Keratinocytes in the Inflamed Adult Skin Modulates T-Cell Auto-Reactivity  Michael Meister, Amel Tounsi, Evelyn Gaffal, Tobias.
Volume 25, Issue 11, Pages (November 2017)
Local Expression of TNFα in Neonatal NOD Mice Promotes Diabetes by Enhancing Presentation of Islet Antigens  E.Allison Green, Elizabeth E. Eynon, Richard.
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
Volume 35, Issue 1, Pages (July 2011)
Volume 143, Issue 1, Pages (July 2012)
NKT Cells Inhibit the Onset of Diabetes by Impairing the Development of Pathogenic T Cells Specific for Pancreatic β Cells  Lucie Beaudoin, Véronique.
Volume 77, Issue 5, Pages (March 2010)
Third-party Mesenchymal Stem Cells Improved Human Islet Transplantation in a Humanized Diabetic Mouse Model  Hao Wu, Di Wen, Ram I Mahato  Molecular Therapy 
Ryang Hwa Lee, Nara Yoon, John C. Reneau, Darwin J. Prockop 
Volume 34, Issue 5, Pages (May 2011)
NKG2D Blockade Prevents Autoimmune Diabetes in NOD Mice
Volume 20, Issue 11, Pages (November 2012)
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Volume 11, Issue 3, Pages (September 2018)
Volume 8, Issue 5, Pages (May 2017)
Volume 33, Issue 4, Pages (October 2010)
Pei Xiong Liew, Woo-Yong Lee, Paul Kubes  Immunity 
Volume 43, Issue 2, Pages (August 2015)
Volume 15, Issue 3, Pages (April 2016)
Volume 35, Issue 2, Pages (August 2011)
Volume 19, Issue 9, Pages (May 2017)
E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity  Jee H. Lee, Chris Elly,
Volume 31, Issue 4, Pages (October 2009)
Volume 34, Issue 5, Pages (May 2011)
IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis  Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,
Volume 41, Issue 4, Pages (October 2014)
Katelyn T. Byrne, Robert H. Vonderheide  Cell Reports 
Volume 26, Issue 2, Pages (February 2018)
Volume 23, Issue 1, Pages (January 2015)
Volume 2, Issue 3, Pages (March 2014)
Volume 26, Issue 1, Pages (January 2018)
Volume 32, Issue 1, Pages (January 2010)
Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand  Yelena Glinka,
TSG-6 suppressed APC activation in vitro and in vivo.
Volume 25, Issue 4, Pages (April 2017)
Molecular Therapy - Methods & Clinical Development
Volume 149, Issue 1, Pages (July 2015)
Volume 19, Issue 6, Pages (May 2017)
Repulsive Guidance Molecule-a Is Involved in Th17-Cell-Induced Neurodegeneration in Autoimmune Encephalomyelitis  Shogo Tanabe, Toshihide Yamashita  Cell.
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Volume 8, Issue 5, Pages 1214-1225 (May 2017) MSC-derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models: Type 1 Diabetes and Uveoretinitis  Taeko Shigemoto-Kuroda, Joo Youn Oh, Dong-ki Kim, Hyun Jeong Jeong, Se Yeon Park, Hyun Ju Lee, Jong Woo Park, Tae Wan Kim, Su Yeon An, Darwin J. Prockop, Ryang Hwa Lee  Stem Cell Reports  Volume 8, Issue 5, Pages 1214-1225 (May 2017) DOI: 10.1016/j.stemcr.2017.04.008 Copyright © 2017 The Authors Terms and Conditions

Figure 1 MSCs and MSC-derived EVs Delay the Onset of T1D in Mice (A) Experimental scheme. On day 0, MSCs (1 × 106 cells), EVs (3 μg or 30 μg), or vehicle control were intravenously (IV) infused immediately after injection of splenocytes from diabetic NOD mice into NOD/scid mice. On day 4, MSCs, EVs, or vehicle control were infused again. Mice were monitored for hyperglycemia. (B) Diabetes incidence. PBS (n = 18); 3 μg EVs (n = 8); 30 μg EVs (n = 10); HBSS (n = 10); MSCs (n = 10). p Value by Kaplan-Meier estimator. Stem Cell Reports 2017 8, 1214-1225DOI: (10.1016/j.stemcr.2017.04.008) Copyright © 2017 The Authors Terms and Conditions

Figure 2 MSC-derived EVs Suppress Insulitis in Islets (A) The animals from Figure 1B were killed on day 58 (EV-treated group) and day 50 (MSC-treated group) for tissue harvesting and blood collection, respectively. Representative H&E staining of the pancreases. Arrows indicate islet-infiltrating immune cells. The control pancreas (Con) was obtained from age-matched NOD/scid mice. (B) Number of islets in the pancreas per slide (50 mm2; the bar represents the mean + SD; ∗∗p < 0.01, ∗∗∗p < 0.001 by one-way ANOVA with Dunnett's Multiple Comparison Test), the percentage of islets in each of the infiltration categories (no insulitis, score 0; peri-insular [<25%], score 1; 25–50% islets infiltrated, score 2; >50% islet infiltrated, score 3; 100% islet infiltrated, score 4) (∗∗∗∗p < 0.0001 by two-way ANOVA) and insulitis scores (∗∗p < 0.01; ∗∗∗p < 0.001 by one-way ANOVA). Five slides per mouse (three or five mice per group) were analyzed. (C) Expression of insulin in the plasma. The bar represents the mean + SD. ∗p < 0.05, ∗∗p < 0.01 by one-way ANOVA with Tukey's multiple comparison test. (D) Representative immunofluorescence staining for insulin (green) and CD4 (red). Nuclei were counterstained with DAPI (blue). Arrows indicate expression of insulin and arrowheads indicate CD4 signals. Scale bar, 100 μm. Stem Cell Reports 2017 8, 1214-1225DOI: (10.1016/j.stemcr.2017.04.008) Copyright © 2017 The Authors Terms and Conditions

Figure 3 MSCs and MSC-derived EVs Prevent Development of EAU in Mice (A) Experimental scheme. On day 0, EAU was induced by subcutaneous IRBP injection and intraperitoneal pertussis toxin injection. Right after induction, either MSCs (1 × 106 cells) or MSC-derived EVs (30 μg containing 15 × 109 EVs) were injected into the tail vein. As a control, the same volume of PBS was injected. On day 21, the eyeballs and draining cervical lymph nodes were collected for assays. (B) Representative microphotographs of H&E staining of the eyes (100× magnification), and histologic disease scores of retinal pathology. (C) Representative microphotographs of CD3 immunostaining of the eyes (100× magnification), and quantitative data of the number of CD3+ cells infiltrating the retina and vitreous cavity. Dots represent a single animal, and the data are presented as means ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 by one-way ANOVA. Stem Cell Reports 2017 8, 1214-1225DOI: (10.1016/j.stemcr.2017.04.008) Copyright © 2017 The Authors Terms and Conditions

Figure 4 MSC-Derived EVs Suppress Th1 and Th17 Development in EAU Mice (A) Relative quantification (RQ) of Th1 and Th17 cytokines in the eyes of the animals from Figure 3A with real-time RT-PCR assays. Data (mean + SD) were obtained from six mice per group. (B) Representative flow cytometry plots and quantitative results for Th1 and Th17 cells in cervical lymph nodes (CLNs) collected from animals as in Figure 3A. Dots indicate a single animal in (B). The bar represents the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 by one-way ANOVA. Stem Cell Reports 2017 8, 1214-1225DOI: (10.1016/j.stemcr.2017.04.008) Copyright © 2017 The Authors Terms and Conditions

Figure 5 MSC-Derived EVs Suppress Th1 and Th17 Development in the MLR (A) Splenic Th1 cytokine expressions at day 5 (IFN-γ; n = 3 for MSCs and n = 4 for EVs) and day 2 (IL-12 p70; n = 3 and TNF-α; n = 4) in the MLR with or without MSCs or MSC-derived EVs. Ratio of MSCs to splenocytes = 1:15, 1: 30, and 1: 60. (B) Th17 cytokine expression at day 2 (IL-6; n = 4) and day 5 (IL-6 and IL-17A/F; n = 3) in the MLR with or without MSC-derived EVs. (C) Representative flow cytometry plots of CD4+CD25+FOXP3+ cells in the MLR assay with or without MSC-derived EV treatment. The cells were first gated on CD4 expression and further analyzed for the expression of CD25 and FOXP3. (D) Expression of IL-10 at day 5 in the MLR with or without MSC-derived EVs (n = 4). Dots indicate independent experiments and all values are means ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 by one-way ANOVA. Stem Cell Reports 2017 8, 1214-1225DOI: (10.1016/j.stemcr.2017.04.008) Copyright © 2017 The Authors Terms and Conditions

Figure 6 MSC-Derived EVs Suppress Activation of APCs and T Cells in the MLR (A–C) Representative flow cytometry plots (A and B) and quantification (C) of CD80, CD86, CD40, and MHC-class-II-positive cells in CD11c+ cells on day 2 of the MLR assay with or without MSC-derived EV treatment. The cells were first gated on CD11c expression, and further analyzed for the expression of CD80, CD86, CD40, and MHC class II (n = 3). (D) Expression of IL-10 at day 2 in the MLR with or without MSC-derived EVs (n = 3 for control; n = 4 for EVs). (E) Quantification of flow cytometry analysis of CD40, and MHC-class-II-positive cells in CD11c+ cells on day 2 of the MLR assay with CD11c+ responder cells (n = 3). (F) Expression of IL-2 and IFN-γ in CD4-positive cells at day 2 upon CD3/28 bead stimulation (n = 4). Dots indicate independent experiments and all values are means ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 by one-way ANOVA. Stem Cell Reports 2017 8, 1214-1225DOI: (10.1016/j.stemcr.2017.04.008) Copyright © 2017 The Authors Terms and Conditions